James V. Fiorica

<i>BRCA1</i> and <i>BRCA2</i> mutations account for a large proportion of ovarian carcinoma cases

Tuya Pal, Jenny Permuth‐Wey, Judith A. Betts et al. · Cancer · 2005 · 688 citations

Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study

Harry J. Long, Brian N. Bundy, Edward C. Grendys et al. · Journal of Clinical Oncology · 2005 · 554 citations

Lysophospholipids Are Potential Biomarkers of Ovarian Cancer

Rebecca Sutphen, Yan Xu, George D. Wilbanks et al. · Cancer Epidemiology Biomarkers & Prevention · 2004 · 336 citations

Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer.

Tatiana Gritsko, Domenico Coppola, June E. Paciga et al. · PubMed · 2003 · 305 citations

Human Ovarian Cancer, Pathology, Ovarian Cancer Progression +17

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Gini F. Fleming, Michael W. Sill, Kathleen M. Darcy et al. · Gynecologic Oncology · 2009 · 295 citations · Full text

Phase Ii Trial, Medicine, Cancer Management +6